Related Experiment Video

Updated: Jun 20, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Cardiovascular effects of losartan and its relevant clinical application

Feichao Xu1, Caiping Mao, Yali Hu

  • 1Perinatal Biology Center, Soochow University, Suzhou 215123, China.

Current Medicinal Chemistry
|September 15, 2009
PubMed

Insights

Losartan, a type 1 angiotensin II receptor (AT1R) antagonist, offers cardiovascular benefits by modulating the renin-angiotensin system (RAS). This review details its effects on the heart and vasculature, aiding future cardiovascular disease treatments.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Molecular Biology

Background:

  • The renin-angiotensin system (RAS) is crucial for cardiovascular homeostasis and disease development.
  • Dysregulated cardiac and vascular RAS contributes to cardiovascular pathologies.
  • Losartan is an established AT1R antagonist used for hypertension and other cardiovascular conditions.

Purpose of the Study:

  • To review the direct and indirect cardiovascular effects of losartan.
  • To elucidate the mechanisms of losartan's action on the heart and vasculature.
  • To provide insights for developing novel cardiovascular therapeutics.

Main Methods:

  • Literature review of studies on losartan's cardiovascular effects.
  • Analysis of the chemical basis of AT1R antagonism by losartan.
  • Synthesis of information on losartan's mechanisms in cardiac and vascular tissues.

Main Results:

  • Losartan exerts direct and indirect effects on cardiac and vascular functions.
  • Its mechanism involves selective blockade of the angiotensin II type 1 receptor (AT1R).
  • Evidence supports its role in managing cardiovascular diseases through RAS modulation.

Conclusions:

  • Losartan's AT1R antagonism provides a basis for its cardiovascular protective effects.
  • Understanding these mechanisms can guide the development of new cardiovascular drugs.
  • Targeting the RAS remains a key strategy in combating cardiovascular diseases.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...